CEFQUINOME

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H24N6O5S2
Molecular Weight	528.604
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12SCC(C[N+]3=C4CCCCC4=CC=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C5=CSC(N)=N5)C([O-])=O

InChI

InChIKey=YWKJNRNSJKEFMK-PQFQYKRASA-N

InChI=1S/C23H24N6O5S2/c1-34-27-16(14-11-36-23(24)25-14)19(30)26-17-20(31)29-18(22(32)33)13(10-35-21(17)29)9-28-8-4-6-12-5-2-3-7-15(12)28/h4,6,8,11,17,21H,2-3,5,7,9-10H2,1H3,(H3-,24,25,26,30,32,33)/b27-16-/t17-,21-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C23H24N6O5S2
Molecular Weight	528.604
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	1
Optical Activity	UNSPECIFIED

Description
Sources: http://www.msd-animal-health.co.in/products/cobactan_2.5/020_product_details.aspx

Cefquinome is a 4th generation cephalosporin which is active against a broad spectrum of Gram positive and Gram negative bacteria. As many cephalosporin it acts by binding to bacterial PBP and thus inhibiting the cell wall synthesis. Cefquinome is approved for veterinary use in cattles with respiratory tract infections, skin infections, bacterial mastitis and septicaemia.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial penicillin-binding protein 233 Target ID: CHEMBL2354204 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004307.pdf	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Sub-clinical mastitis 5 Sources: http://www.msd-animal-health.co.in/products/cobactan_2.5/020_product_details.aspx	Curative	Approved 8429	COBACTAN Approved Use Treatment of infections caused by bacteria sensitive to cefquinome, such as: (1) Respiratory tract infections caused by Pasteurella multocida and Mannheimia haemolytica. (2) Digital dermatitis, infectious bulbar necrosis and interdigital necrobacillosis (foul in foot). (3) Acute E.coli mastitis with signs of systemic involvement. (4) Calf-E.coli septicaemia. Launch Date 1.15611835E12
Respiratory tract infections 85 Sources: http://www.msd-animal-health.co.in/products/cobactan_2.5/020_product_details.aspx	Curative	Approved 8429	COBACTAN Approved Use Treatment of infections caused by bacteria sensitive to cefquinome, such as: (1) Respiratory tract infections caused by Pasteurella multocida and Mannheimia haemolytica. (2) Digital dermatitis, infectious bulbar necrosis and interdigital necrobacillosis (foul in foot). (3) Acute E.coli mastitis with signs of systemic involvement. (4) Calf-E.coli septicaemia. Launch Date 1.15611835E12
Septicaemia 15 Sources: http://www.msd-animal-health.co.in/products/cobactan_2.5/020_product_details.aspx	Curative	Approved 8429	COBACTAN Approved Use Treatment of infections caused by bacteria sensitive to cefquinome, such as: (1) Respiratory tract infections caused by Pasteurella multocida and Mannheimia haemolytica. (2) Digital dermatitis, infectious bulbar necrosis and interdigital necrobacillosis (foul in foot). (3) Acute E.coli mastitis with signs of systemic involvement. (4) Calf-E.coli septicaemia. Launch Date 1.15611835E12
Digital dermatitis 2 Sources: http://www.msd-animal-health.co.in/products/cobactan_2.5/020_product_details.aspx	Curative	Approved 8429	COBACTAN Approved Use Treatment of infections caused by bacteria sensitive to cefquinome, such as: (1) Respiratory tract infections caused by Pasteurella multocida and Mannheimia haemolytica. (2) Digital dermatitis, infectious bulbar necrosis and interdigital necrobacillosis (foul in foot). (3) Acute E.coli mastitis with signs of systemic involvement. (4) Calf-E.coli septicaemia. Launch Date 1.15611835E12
Infectious bulbar necrosis 2 Sources: http://www.msd-animal-health.co.in/products/cobactan_2.5/020_product_details.aspx	Curative	Approved 8429	COBACTAN Approved Use Treatment of infections caused by bacteria sensitive to cefquinome, such as: (1) Respiratory tract infections caused by Pasteurella multocida and Mannheimia haemolytica. (2) Digital dermatitis, infectious bulbar necrosis and interdigital necrobacillosis (foul in foot). (3) Acute E.coli mastitis with signs of systemic involvement. (4) Calf-E.coli septicaemia. Launch Date 1.15611835E12
Interdigital necrobacillosis 2 Sources: http://www.msd-animal-health.co.in/products/cobactan_2.5/020_product_details.aspx	Curative	Approved 8429	COBACTAN Approved Use Treatment of infections caused by bacteria sensitive to cefquinome, such as: (1) Respiratory tract infections caused by Pasteurella multocida and Mannheimia haemolytica. (2) Digital dermatitis, infectious bulbar necrosis and interdigital necrobacillosis (foul in foot). (3) Acute E.coli mastitis with signs of systemic involvement. (4) Calf-E.coli septicaemia. Launch Date 1.15611835E12

PubMed

Title	Date	PubMed
Antibacterial activities in vitro and in vivo and pharmacokinetics of cefquinome (HR 111V), a new broad-spectrum cephalosporin.	1991 Jan	2014969
In vitro activities of cephalosporins and quinolones against Escherichia coli strains isolated from diarrheic dairy calves.	1999 Mar	10049259
Selection and persistence of CTX-M-producing Escherichia coli in the intestinal flora of pigs treated with amoxicillin, ceftiofur, or cefquinome.	2008 Oct	18644956
Factors affecting cure when treating bovine clinical mastitis with cephalosporin-based intramammary preparations.	2009 May	19389951
Development and validation of a high-performance liquid chromatography method for determination of cefquinome concentrations in sheep plasma and its application to pharmacokinetic studies.	2011 Feb	21098247
Development of stability-indicating methods for cefquinome sulphate.	2013 Sep	24170991
Comparative Pharmacokinetics of Cefquinome (Cobactan 2.5%) following Repeated Intramuscular Administrations in Sheep and Goats.	2014	26464946
Stability-indicating HPLC method for the determination of cefquinome sulfate.	2014 Mar-Apr	25272644

Patents

Sample Use Guides

In Vivo Use Guide

1 mg cefquinome/kg (2ml/50 kg body wt.) or 2 mg cefquinome/kg (4ml/50 kg body wt.) given by intramuscular injection (2,5% Cobactan solution).

Route of Administration: Intramuscular

In Vitro Use Guide

The MICs of cefquinome against single laboratory strains of gram-positive and gram-negative anaerobic bacteria were determined. The values were (MIC50): 0.781 ug/ml for Staphylococcus aureus (Methicillin susceptible); 12.5 ug/ml for Staphylococcus aureus (Methicillin resistant); <0.006 ug/ml for Streptococcus spp.; 4.0 ug/ml for Enterococci; 0.049 ug/ml for E.Coli and Klebsiella spp.; 0.098 ug/ml for Salmonella spp., Enterobacter spp. and Proteus mirabilis; 0.195 ug/ml for Serratia marcescens and Proteus spp.; 0.002 ug/ml for Streptococcus pyogenes; 0.008 ug/ml for Streptococcus pneumoniae and Klebsiella pneumoniae; 0.078 ug/ml for Pasteurella multocida, Proteus mirabilis ATCC 14273; 0.03 ug/ml for Escherichia coli 078 and 0.06 ug/ml for Salmonella typhimurium MZ II.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:12:29 UTC 2023` Edited by `admin` on `Fri Dec 15 16:12:29 UTC 2023`
Record UNII	Z74S078CWP
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CEFQUINOME

Official Name

English

1-(((6R,7R)-7-(2-(2-AMINO-4-THIAZOLYL)GLYOXYLAMIDO)-2-CARBOXY-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-EN-3-YL)METHYL)-5,6,7,8-TETRAHYDROQUINOLINIUM HYDROXIDE, INNER SALT, 72-(Z)-(O-METHYLOXIME)

Common Name

English

cefquinome [INN]

Common Name

English

COBACTAN

Brand Name

English

QUINOLINIUM, 1-((7-(((2-AMINO-4-THIAZOLYL)(METHOXYIMINO)ACETYL)AMINO)-2-CARBOXY-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-EN-3-YL)METHYL)-5,6,7,8-TETRAHYDRO-, HYDROXIDE, INNER SALT, (6R-(6.ALPHA.,7.BETA.(Z)))-

Common Name

English

HR111V

Code

English

CEFQUINOME [MI]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QJ51DE90